K2 Principal Fund, L.P. Alnylam Pharmaceuticals, Inc. Transaction History
K2 Principal Fund, L.P.
- $307 Million
- Q4 2024
A detailed history of K2 Principal Fund, L.P. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 30,100 shares of ALNY stock, worth $7.02 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
30,100Holding current value
$7.02 Million% of portfolio
0.23%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
670Shares Held
112MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$3.87 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$2.97 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.23 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.62 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.02 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $28.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...